The biotech drugmaker said it will buy Impact Biomedicines for $1.1 billion, with up to $5.9 billion in other potential payments. NuVasive Inc., down $5.45 to $55.56. The spinal device maker gave a disappointing forecast for 2018. Crocs Inc., up $1.03 to $13.23. The shoe company raised its sales…
News
- Celgene, Dave & Buster's slide while Kohl's and Crocs rise
- GenCure expansion to bolster SA role in regenerative medicine
GenCure has begun work on a significant expansion that will greatly enhance the scope of the San Antonio-based company's work in the cellular ... That's created concerns in the biotech industry as Capp said research is outpacing the build up of brick-and-mortar support needed to advance the…
- Novo Nordisk revises up offer for Ablynx to $3.1 billion
HELSINKI (AP) — Danish drugmaker Novo Nordisk has revised up its offer for Belgian biotech company Ablynx as it looks to find growth opportunities beyond its core business. The Copenhagen-based company said Monday it is offering up to 30.50 euros for each Ablynx share, valuing the company at…
- Celgene, Dave & Buster's slide while Kohl's and Crocs rise
The action camera maker said demand was weak over the holidays, and said it's lowering its forecast and cutting jobs. Celgene Corp., down 81 cents to $104.18. The biotech drugmaker said it will buy Impact Biomedicines for $1.1 billion, with up to $5.9 billion in other potential payments.
- bioAffinity Technologies to Present at Biotech Showcase™ Annual Conference
SAN ANTONIO, Texas, Jan. 05, 2018 (GLOBE NEWSWIRE) -- bioAffinity Technologies, a privately held cancer diagnostics company, today announced that it will present its proprietary technology to detect and treat multiple cancers at the cellular level at Biotech Showcase™ 2018, an annual investor…